

## **Product datasheet for TL301964V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **RNF14 Human shRNA Lentiviral Particle (Locus ID 9604)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** RNF14 Human shRNA Lentiviral Particle (Locus ID 9604)

**Locus ID:** 9604

Synonyms: ARA54; HFB30; HRIHFB2038; TRIAD2

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** RNF14 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001201365, NM 004290, NM 183398, NM 183399, NM 183400, NM 183401,

NM 004290.1, NM 004290.2, NM 004290.4, NM 183400.1, NM 183400.2, NM 183401.1, NM 183401.2, NM 183398.1, NM 183398.2, NM 183399.1, NM 183399.2, NM 001201365.1,

BC126185, BC144061, NM 183400.3, NM 183401.3, NM 004290.5

UniProt ID: Q9UBS8

**Summary:** The protein encoded by this gene contains a RING zinc finger, a motif known to be involved in

protein-protein interactions. This protein interacts with androgen receptor (AR) and may function as a coactivator that induces AR target gene expression in prostate. A dominant negative mutant of this gene has been demonstrated to inhibit the AR-mediated growth of prostate cancer. This protein also interacts with class III ubiquitin-conjugating enzymes (E2s) and may act as a ubiquitin-ligase (E3) in the ubiquitination of certain nuclear proteins. Six alternatively spliced transcript variants encoding two distinct isoforms have been reported.

[provided by RefSeq, Jan 2011]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).